NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by NeuroSense Therapeutics Ltd. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for NeuroSense Therapeutics Ltd., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Eisenberg Or | Chief Financial Officer | 1,504,050 | Jun 17, 2026 | 2 |
| Ben-Noon Alon | Chief Executive Officer | 4,534,233 | Jun 17, 2026 | 1 |
| Binder Hagit | General Manager | 521,806 | Mar 30, 2026 | 1 |
| Russek-Blum Niva | Chief Technology Officer | 467,953 | Mar 30, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Ben-Noon AlonChief Executive Officer | PPurchase | +250.0K | $0.80 | +$200.0K | +5.8%4.53M after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Eisenberg OrChief Financial Officer | PPurchase | +250.0K | $0.80 | +$200.0K | +19.9%1.50M after |